[Form 4] Cue Biopharma, Inc. Insider Trading Activity

Q: When do Lucinda Warren’s Cue Biopharma (CUE) stock options expire?

The granted stock options expire on April 8, 2036 . After this expiration date, any unexercised options will lapse and can no longer be used to purchase Cue Biopharma common shares, setting a long-term window for potential exercise.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cue Biopharma, Inc. reported that Chief Business Officer Lucinda Warren received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.

The award vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Warren holds 250,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Warren Lucinda

Role CHIEF BUSINESS OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	250,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 250,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 250,000 options Exercise price: $0.29 per share Underlying shares: 250,000 shares +2 more

5 metrics

Stock options granted 250,000 options Grant to Chief Business Officer on April 9, 2026

Exercise price $0.29 per share Strike price for granted stock options

Underlying shares 250,000 shares Common stock underlying the options

Expiration date April 8, 2036 Option term for the grant

Post-grant option holdings 250,000 options Total stock options held directly after the grant

Key Terms

Stock Option (right to buy), exercise price, vesting, semi-annual installments, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "0.2900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

semi-annual installments financial

"the remainder vesting in equal, semi-annual installments thereafter"

expiration date financial

"expiration_date: "2036-04-08T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

04/10/2026 - 04:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Warren Lucinda

(Last)

(First)

(Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON

MASSACHUSETTS

02135

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF BUSINESS OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$0.29	04/09/2026		A		250,000		⁽¹⁾	04/08/2036	Common Stock	250,000	$0.0	250,000	D

Explanation of Responses:

1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.

	/s/ Lucinda Warren	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Cue Biopharma (CUE) report for Lucinda Warren?

Cue Biopharma reported that Chief Business Officer Lucinda Warren received a grant of 250,000 stock options. These options give her the right to buy common shares at a fixed price, aligning part of her compensation with the company’s future share performance over time.

What is the exercise price of Lucinda Warren’s new stock options at Cue Biopharma (CUE)?

The stock options granted to Lucinda Warren have an exercise price of $0.29 per share. This means she can purchase Cue Biopharma common stock at $0.29 once the options vest, regardless of the market price at the time of exercise.

How do Lucinda Warren’s Cue Biopharma (CUE) stock options vest over time?

Lucinda Warren’s options vest over four years, with 25% becoming exercisable on the one-year anniversary of the grant date. The remaining 75% then vest in equal semi-annual installments, gradually increasing her exercisable option position during the vesting period.

When do Lucinda Warren’s Cue Biopharma (CUE) stock options expire?

The granted stock options expire on April 8, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase Cue Biopharma common shares, setting a long-term window for potential exercise.

How many Cue Biopharma (CUE) stock options does Lucinda Warren hold after this grant?

Following this grant, Lucinda Warren holds 250,000 stock options directly. All of these options relate to Cue Biopharma common stock, with vesting conditions and a long-dated expiration that tie her potential upside to the company’s long-term performance.